ClinicalTrials.gg
CompletedNCT03458481Updated Mar 18, 2020

Phase 2 Study of Yimitasvir Phosphate Capsules

A Phase 2 interventional study of SOF and DAG181 in Chronic HCV Infection, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 17 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-18.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jul 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection

Read the detailed description

A phase 2, multicenter, randomized, parallel Assigned, open-label study to explore the safety, tolerability and antiviral activity of DAG181/SOF combination for 12 weeks in adult subjects with chronic genotype 1 HCV infection.

Approximately 120 HCV genotype 1 subjects without cirrhosis will be enrolled, treatment-experienced subjects are ≤20%, all subjects will be randomized (1:1) to one of the following two treatment groups by IWRS (Medidata Balance): a) DAG181 100 mg/ SOF 400 mg once daily for 12 weeks, b) DAG181 200 mg/ SOF 400 mg once daily for 12 weeks. Randomization will be stratified by "treatment-naive" or "treatment-experienced".

02

Conditions studied

  • Chronic HCV Infection

Keywords

  • Chronic Genotype 1 HCV Infection
03

In context

Lead sponsor

Sunshine Lake Pharma Co., Ltd. is the lead sponsor of 83 studies on the registry; 13 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide written ;
  2. Male or female, age≥18 years;
  3. A female subject is eligible to enter the study if it is confirmed that she is:

    1. Of non- (i.e., women who have had a hysterectomy, have both ovaries removed or medically documented ovarian failure, or are -women > 50 years of age with cessation (for≥12 months) of previously occurring menses), or
    2. Of childbearing potential (Women≤50 years of age with amenorrhea will be considered to be of childbearing potential). These women must have a negative serum pregnancy test at screening, and must use specific methods from screening until 4 weeks after last dose of study drugs, such as complete abstinence from intercourse, vaginal ring, cervical cap or contraceptive diaphragm, IUD, etc.
  4. All male study subjects must agree to consistently and correctly use specific contraceptive methods with their female partner from screening until 4 weeks after last dose of study drugs(except of surgical sterilization), such as complete abstinence from intercourse, condom, and their female partner use contraceptives , vaginal ring , cervical cap or contraceptive diaphragm, IUD, etc.
  5. Male subjects must agree to refrain from sperm donation from the date of screening until 4 weeks after the last dose of study drugs;
  6. (BMI)≥18.0 and≤32.0 kg/m2, and Weight≥40 kg;
  7. Confirmation of chronic infection documented by either:

    1. A positive anti-HCV antibody test or positive HCV RNA or positive HCV genotyping test at least 6 months prior to the Baseline/Day 1 visit, or
    2. A liver performed prior to the Baseline/Day 1 visit with evidence of chronic HCV infection.
  8. Serological detection of anti-HCV antibodies was positive at screening;
  9. HCV RNA≥1×104 IU/mL at Screening;
  10. HCV genotype 1a, 1b, or mixed 1a/1b at screening as determined by the Central Laboratory;
  11. Classification as treatment naive or treatment experienced:

    1. Treatment naive is defined as having never been exposed to approved or experimental HCV-specific direct-acting antiviral agents or prior treatment of HCV with interferon (with or without ribavirin);
    2. Treatment experienced is defined as prior treatment failure to a regimen containing interferon (IFN-α,β or Peg-IFN±RBV) that was completed at least 2 months prior to screening. and the subject's medical records must include sufficient detail of prior virologic failure to allow for categorization of prior response, as either:

    i) Non-Responder: Decrease of HCV RNA\<2 log at week 12 compared to baseline; ii) Partially-Responder: Decrease of HCV RNA>2 log at week 12 compared to baseline, and detectable HCV RNA levels within week 12 and week 24; iii) Breakthrough/Relapse: Subject achieved undetectable HCV RNA levels (HCV RNA \< LLOQ) during treatment, but did not achieve sustained virologic response (SVR); iv) Intolerance: Subjects have discontinued interferon-based treatment due to intolerance which proved by chief complaint or medical records.

  12. Absence of cirrhosis is defined as any one of the following:

    1. Liver biopsy within 2 years of Screening or at Screening showing absence of cirrhosis (e.g. Metavir score=0-3 or Ishak score\<5), or
    2. Fibroscan within 6 months of Screening or at Screening with a result of ≤12.5 kPa.

    liver biopsy results will supersede fibroscan results and be considered definitive.

  13. Subject must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:

  1. Current or prior history of any of the following:

    1. Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage);
    2. Chronic liver disease of a non- etiology (Including but not limited to hemochromatosis, Wilson's disease,alfa-1 antitrypsin deficiency);
    3. Significant cardiac disease(Including but not limited to myocardial infarction, bradycardia) ;
    4. Significant pulmonary disease;
    5. Malabsorption syndrome or gastrointestinal disorder or post operative condition that could interfere with the absorption of the study drug;
    6. Central nervous system trauma, epilepsy, stroke or ;
    7. Psychiatric illness or psychological disease or relevant medical history;
    8. diagnosed before signing the form ( except for specific cancers that have been cured by surgical resection (basal cell skin cancer, etc) or cervical carcinoma in situ are allowed). subjects under evaluation for malignancy are not eligible;
    9. Solid organ transplantation;
    10. Subjects have any other medical disorder that may interfere with subjects treatment, assessment or compliance with the protocol.
  2. Subjects has the following laboratory parameters at screening:

    1. > 10×the (ULN);
    2. AST > 10×ULN;
    3. Total > 1.5 × ULN;
    4. Albumin\< 3.5 g/dL;
    5. AFP>100 ng/mL; If 20 ng/mL≤AFP≤100 ng/mL, a liver ultrasound examination is required to exclude subjects suspected of hepatocellular carcinoma;
    6. > 1.5 x ULN;
    7. \<11 g/dL for female subjects; \<12 g/dL for male subjects;
    8. \<90 x109/L;
    9. Neutrophil absolute count\< 1.5 ×109/L;
    10. > 8.5%;
    11. (CLcr) \<50 mL /min as calculated by the Cockcroft-Gault equation;
    12. serology test results were positive;
    13. antibody test results were positive.
  3. Screening with abnormalities;
  4. Prior exposure to approved or experimental HCV-specific direct-acting antiviral agent;
  5. Use of any prohibited concomitant medications;
  6. Significant drug allergy, or known to DAG181, SOF and its metabolites, or formulation recipients;
  7. A positive drug screen at screening will exclude subjects unless it can be explained by non-prescription drug or prescribed medication; the diagnosis and prescription must be approved by the investigator;
  8. Pregnant or nursing female or male with pregnant female partner.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    SOF+DAG181 100 mg

    Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 100 mg for 12 weeks.

    Drug: SOF · Drug: DAG181

  • Experimental
    SOF+DAG181 200 mg

    Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 200 mg for 12 weeks.

    Drug: SOF · Drug: DAG181

Interventions

  • DrugSOF

    400 mg tablet administered orally once daily

    Also known as: sofosbuvir, Sovaldi®

  • DrugDAG181

    Capsule administered orally once daily

    Also known as: Yimitasvir

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment

    Time frame: Posttreatment Week 12

  2. Safety and tolerability were evaluated based on adverse event monitoring, laboratory tests, 12-lead ECG assessments, vital signs measurements and physical examinations.

    Time frame: Up to posttreatment week 24

Secondary outcomes

  1. Percentage of subjects with sustained virologic response 4, 8 and 24 weeks after discontinuation of therapy (SVR4,SVR8 and SVR24)

    SVR4,SVR8 and SVR24 were defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 4, 8 and 24 weeks after stopping study treatment, respectively.

    Time frame: Posttreatment Weeks 4,8 and 24

  2. Percentage of subjects with HCV RNA < the lower limit of quantitation (LLOQ) while on treatment

    Time frame: Baseline to week 12

  3. The time to first achieve "HCV RNA < the lower limit of quantitation (LLOQ)" while on treatment

    Time frame: Baseline to week 12

  4. HCV RNA change from baseline

    Time frame: Up to posttreatment week 24

  5. Percentage of subjects with virologic failure

    Virologic failure was defined as: 1. On-treatment virologic failure: Breakthrough (confirmed HCV RNA ≥the lower limit of quantitation (LLOQ) after having previously had HCV RNA \<the lower limit of quantitation (LLOQ) while on treatment), or Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or Non-response (HCV RNA persistently ≥the lower limit of quantitation (LLOQ) through 8 weeks of treatment); 2. Virologic relapse: Confirmed HCV RNA ≥the lower limit of quantitation (LLOQ) during the posttreatment period having achieved HCV RNA \<the lower limit of quantitation (LLOQ) at last on-treatment visit.

    Time frame: Up to posttreatment week 24

  6. Viral resistance

    Viral resistance to DAG181 and/or SOF during treatment and after cessation of treatment

    Time frame: Up to posttreatment week 24

07

Study locations

17 sites
  • Peking University First Hospital
    Beijing, Beijing 100034, China
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
  • Beijing YouAn Hospital,Capital Medical University
    Beijing, Beijing 100069, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
  • Guangzhou Eighth People's Hospital
    Guangzhou, Guangdong 510060, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Hainan General Hospital
    Haikou, Hainan 570311, China
  • The Third Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050051, China
  • Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University Science & Technology
    Wuhan, Hubei 430030, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • Xiangyan Hospital, Central South University
    Changsha, Hunan 410008, China
  • The Second Hospital of Nanjing
    Nanjing, Jiangsu 210003, China
  • The First Affiliated Hospital of NanChang University
    Nanchang, Jiangxi 330006, China
  • The First Hospital of Jilin University
    Chang Chun, Jilin 130021, China
  • Tangdu Hospital
    Xi'an, Shanxi 710038, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in May 2018, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2018
First posted
Mar 8, 2018
StartActual
Jul 31, 2017
Primary completionActual
May 8, 2018
CompletionActual
Sep 26, 2018
Last update
Mar 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03458481
Responsible party
Sponsor
First posted
Mar 8, 2018
Start date
Jul 31, 2017
Primary completion
May 8, 2018
Completion
Sep 26, 2018
Last update
Mar 18, 2020

Study contacts

Lai Wei, Doctor
study chair · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yimitasvir

Start the discussion